Articles
11 June 2009
Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009
https://doi.org/10.4081/hmr.v3i1.542

Gemcitabine

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
197
Views
187
Downloads

Authors

M Tani
support@pagepress.org
L Alinari
A Broccoli
E Derenzini
M Fina
L Gandolfi
E Marchi
C Pellegrini
V Stefoni
F Venturini
PL Zinzani
Gemcitabine (2',2'-difluorodeoxy- cytidine, dFdC) is an analog of deoxycytidine. It is transformed to the active triphosphate (dFdCTP) after intracellular phosphorylation. Gemcitabine monophosphate is inserted into the DNA and inhibits DNA elongation as a false nucleotide. In contrast to other antimetabolites, an additional, altered nucleotide is inserted behind dFdC inhibiting repair mechanisms (masked chain termination).

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Gemcitabine. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.542